In the Claims:

Please amend the claims, so that the following list is a clean version of the pending claims:

1. (currently amended) A compound having the formula (I),



(I)

a N-oxide form, stereochemical isomer, racemic mixture, salt, prodrug, ester or metabolite thereof,

wherein

A is aryl, heteroaryl or heterocycloalkyl;

R^1 represents hydrogen, halogen, hydroxy, amino, nitro, alkyl, alkyloxy, or a radical of formula (II),



(II)

R^2 represents alkyl, alkenyl, alkynyl, hydroxy, halogen, nitro, cyano, amino, haloalkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, R^8-O-, R^8-S-, R^8-$S(=O)_2$-, R^8-C(=O)-, R^8-C(=S)-, R^8-C(=NH)-, R^8-C(=NCN)-, R^8-NH-, $(R^8)_2$-N-, HO-C(=O)-, NH_2-C(=O)-, NH_2-$S(=O)_2$-, NH_2-C(=S)-, NH_2-C(=NH)-, NH_2-C(=NCN)-, R^8-NR^4-C(=O)-, R^8-NR^4-$S(=O)_2$-, R^8-O-C(=O)-, R^8-C(=O)-NR^4-, R^8-$S(=O)_2$-NR^4-, R^8-C(=O)-O-, R^8-S-CH_2- or R^8-O-CH_2-C(=O)-;

R^3 represents hydroxy, amino, alkyloxy, cycloalkyloxy or mono- or disubstituted amino ~~whereby~~ wherein the substituents can be selected from alkyl and cycloalkyl;

R^4 represents hydrogen, alkyl or cycloalkyl;

R^6 is hydrogen, amino, R^7-C(=O)-, R^8-$S(=O)_2$-NH-, R^8-C(=O)-NH-, R^8-C(=S)-NH-, R^8-C(=NH)-NH-, R^8-C(=NCN)-NH-, R^8-O-C(=O)-NH-, R^8-O-alkanediyl-C(=O)-NH-, R^8-alkanediyl-$S(=O)_2$-NH-, aryl-alkanediyl-C(=O)-NH-, aryl-alkenediyl-C(=O)-NH-, heteroaryl-alkanediyl-C(=O)-NH-, cycloalkyl-alkanediyl-C(=O)-NH-, heterocycloalkyl-alkanediyl-C(=O)-NH- or substituted alkyl ~~whereby~~ wherein the substitutents can be selected from amino, R^7-C(=O)-, R^8-$S(=O)_2$-NH-, R^8-C(=O)-NH-, R^8-C(=S)-NH-, R^8-C(=NH)-NH-, R^8-C(=NCN)-NH-, R^8-O-C(=O)-NH-, R^8-O-alkanediyl-C(=O)-NH-, R^8-alkanediyl-$S(=O)_2$-NH-, aryl-alkanediyl-C(=O)-NH-, heteroaryl-alkanediyl-C(=O)-NH-, cycloalkyl-alkanediyl-C(=O)-NH- and heterocycloalkyl-alkanediyl-C(=O)-NH-;

R^7 represents hydroxy, amino, alkyloxy, cycloalkyloxy or mono- or disubstituted amino ~~whereby~~ wherein the substituents can be selected from alkyl and cycloalkyl;

R^8 represents alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl or heterocycloalkyl;

Y represents alkanediyl, -C(=O)-, -C(=S)-, -C(=NH)-, -C(=NCN)-, -S(=O)-, -$S(=O)_2$-, -C(=O)-CH_2-O-, -C(=O)-O-, -C(=O)-$(CH_2)_p$-, -C(=O)-NH- or –alkenediyl-C(=O)-;

X is a direct bond, –O-, -S-, -$S(=O)_2$-, -O-$S(=O)_2$-, -$S(=O)_2$-O-, -NH-$S(=O)_2$-, -$S(=O)_2$-NH-, -C(=O)-, -C(=S)-, -C(=NH)-, -C(=NCN)-, -O-C(=O)-, -C(=O)-O-, -NH-C(=O)-, -C(=O)-NH- or alkanediyl;

m and n are each independently zero, one or two; and

p is an integer from 1 to 4[[;]].

2. (currently amended) A compound having the formula (III),



(III)

a N-oxide form, a stereochemical isomer, racemic mixture, salt, prodrug, ester or metabolite thereof, wherein

R^1 represents halogen, hydrogen or a radical of formula (II),



(II)

;

R^2 represents alkyl, alkenyl, alkynyl, hydroxy, halogen, nitro, cyano, amino, haloalkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, R^8-O-, R^8-S-, R^8-S(=O)$_2$-, R^8-C(=O)-, R^8-C(=S)-, R^8-C(=NH)-, R^8-C(=NCN)-, R^8-NH-, $(R^8)_2$-N-, HO-C(=O)-, NH_2-C(=O)-, NH_2-S(=O)$_2$-, NH_2-C(=S)-, NH_2-C(=NH)-, NH_2-C(=NCN)-, R^8-NR^4-C(=O)-, R^8-NR^4-S(=O)$_2$-, R^8-O-C(=O)-, R^8-C(=O)-NR^4-, R^8-S(=O)$_2$-NR^4- or R^8-C(=O)-O-;

R^3 represents hydroxy, amino, alkyloxy, cycloalkyloxy or mono- or disubstituted amino ~~whereby~~ wherein the substituents can be selected from alkyl and cycloalkyl;

R^4 represents hydrogen, alkyl or cycloalkyl;

R^6 is hydrogen, amino, R^7-C(=O)-, R^8-S(=O)$_2$-NH-, R^8-C(=O)-NH-, R^8-C(=S)-NH-, R^8-C(=NH)-NH-, R^8-C(=NCN)-NH-, R^8-O-C(=O)-NH-, R^8-O-alkanediyl-C(=O)-NH-, R^8-alkanediyl-S(=O)$_2$-NH-, aryl-alkanediyl-C(=O)-NH-, heteroaryl-alkanediyl-C(=O)-NH-, cycloalkyl-alkanediyl-C(=O)-NH-, heterocycloalkyl-alkanediyl-C(=O)-NH- or substituted alkyl ~~whereby~~ wherein the substitutents can be selected from amino, R^7-C(=O)-, R^8-S(=O)$_2$-NH-, R^8-C(=O)-NH-, R^8-C(=S)-NH-, R^8-C(=NH)-NH-, R^8-C(=NCN)-NH-, R^8-O-C(=O)-NH-, R^8-O-alkanediyl-C(=O)-NH-, R^8-alkanediyl-S(=O)$_2$-NH-, aryl-alkanediyl-C(=O)-NH-, heteroaryl-alkanediyl-C(=O)-NH-, cycloalkyl-alkanediyl-C(=O)-NH- and heterocycloalkyl-alkanediyl-C(=O)-NH-;

R^7 represents hydroxy, amino, alkyloxy, cycloalkyloxy or mono- or disubstituted amino ~~whereby~~ wherein the substituents can be selected from alkyl and cycloalkyl;

R^8 represents alkyl, cycloalkyl, aryl, heteroaryl or heterocycloalkyl;

Y represents alkanediyl, -C(=O)-, -C(=S)-, -C(=NH)-, -C(=NCN)-, -S(=O)-, -S(=O)$_2$-, -C(=O)-CH_2-O-, -C(=O)-O-, -C(=O)-$(CH_2)_p$-;

X is a direct bond, –O-, -S-, -S(=O)$_2$-, -O-S(=O)$_2$-, -S(=O)$_2$-O-, -NH-S(=O)$_2$-, -S(=O)$_2$-NH-, -C(=O)-, -C(=S)-, -C(=NH)-, -C(=NCN)-, -O-C(=O)-, -C(=O)-O-, -NH-C(=O)-, -C(=O)-NH- or alkanediyl;

m and n are each independently zero, one or two; and

p is an integer from 1 to 4[[;]].

3. (currently amended) A compound as claimed in claim 1 ~~or 2 and~~ wherein Y is -C(=O)-, or -$S(=O)_2$-.

4. (currently amended) A compound as claimed in claim 1 ~~or 2 and~~ wherein X is [[a]] -NH-$S(=O)_2$, -$S(=O)_2$-NH-, -NH-C(=O), or -C(=O)-NH-.

5. (currently amended) A compound as claimed in claim 1 ~~or 2 and~~ wherein R^2 is halogen, bromo, chloro, alkyl, alkyloxy haloalkyl, alkenyl, or alkynyl, said substituents being in meta or para position; and n is 1.

6. (currently amended) A compound as claimed in claim 1 ~~or 2 and~~ wherein R^1 is formula (II),



(II)

each R^6 is independently R^7-C(=O)-, R^8-$S(=O)_2$-NH-, or R^8-C(=O)-NH-, said substitutents R^6 are adjacent; in meta and para positions, or in ortho and meta positions; m is 2,

R^7 is hydroxy, or alkyloxy;

R^8 is aryl substituted with one halogen, bromo, chloro alkyl, alkyloxy haloalkyl, alkenyl, or alkynyl, said substituents in meta or para position.

7. (currently amended) A compound as claimed in ~~any one of~~ claim[[s]] 1 ~~to 6~~, wherein said compound is a monomer.

8. (currently amended) A compound as claimed in ~~any one of~~ claim[[s]] 1 ~~to 6~~, wherein said compound is a dimer.

9. (canceled)

10. (currently amended) A method ~~The use of a compound as claimed in any one of claims 1 to 8 for the manufacture of a medicament capable~~ of inhibiting the entry process of the HIV virus into a mammalian host cell, comprising administering to a mammal a medicament, wherein said medicament comprises a compound as claimed in claim 1.

11. (currently amended) A pharmaceutical composition containing a therapeutically effective amount of ~~an active ingredient~~ a compound as claimed in ~~any one of~~ claim[[s]] 1 ~~to 8~~ and one or more pharmaceutically acceptable excipients.

12. (new) A compound as claimed in claim 2 wherein Y is -C(=O)-, or -$S(=O)_2$-.

13. (new) A compound as claimed in claim 2 wherein X is -NH-$S(=O)_2$, -$S(=O)_2$-NH-, -NH-C(=O), or -C(=O)-NH-.

14. (new) A compound as claimed in claim 2 wherein R^2 is halogen, bromo, chloro, alkyl, alkyloxy haloalkyl, alkenyl, or alkynyl, said substituents being in meta or para position; and n is 1.

15. (new) A compound as claimed in claim 2 wherein R^1 is formula (II),



(II)

each R^6 is independently R^7-C(=O)-, R^8-$S(=O)_2$-NH-, or R^8-C(=O)-NH-, said substitutents R^6 are adjacent; in meta and para positions, or in ortho and meta positions;
m is 2,
R^7 is hydroxy, or alkyloxy;
R^8 is aryl substituted with one halogen, bromo, chloro alkyl, alkyloxy haloalkyl, alkenyl, or alkynyl, said substituents in meta or para position.

16. (new) A compound as claimed in claim 2, wherein said compound is a monomer.

17. (new) A compound as claimed in claim 2, wherein said compound is a dimer.

18. (new) A method of inhibiting the entry process of the HIV virus into a mammalian host cell, comprising administering to a mammal a medicament, wherein said medicament comprises a compound as claimed in claim 2.

19. (new) A pharmaceutical composition containing a therapeutically effective amount of a compound as claimed in claim 2 and one or more pharmaceutically acceptable excipients.